|
|
| Atamer,Y.; Atamer,A.; Can,A.S.; Hekimoğlu,A.; Ilhan,N.; Yenice,N.; Koçyiğit,Y.. |
| Human serum paraoxonase contributes to the anti-atherogenic effect of high-density lipoprotein cholesterol (HDL-C) and has been shown to protect both low-density lipoprotein cholesterol (LDL-C) and HDL-C against lipid peroxidation. We investigated the effects of rosiglitazone on paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus [50 patients (30 males, 20 females); mean±SD age: 58.7±9.2 years, body mass index: 28.2±4.1'kg/m2], in whom glucose control could not be achieved despite treatment with metformin, sulphonylurea, and/or insulin. The patients were given 4'mg/day rosiglitazone for 3 months in addition to their usual treatment. Serum paraoxonase activity, malondialdehyde, homocysteine, and lipid profile were... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Rosiglitazone; Diabetes mellitus type 2; Paraoxonase; Lipoproteins; Homocysteine; Lipid peroxidation. |
| Ano: 2013 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013000600528 |
| |
